Jacqueline Zummo
Known title: Chf Scientific Operations OffCIK: 0001798929
Associated companies
Transaction History
| TARA | ▼ Sell | Open Market | 1,134 | $6K | 4/8/2026 | View on chart |
| TARA | ▼ Sell | Open Market | 22,598 | $119K | 4/1/2026 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 3,724 | $25K | 1/26/2026 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 6,578 | $37K | 1/20/2026 | View on chart |
| TARA | ▲ Buy | Grant | 30,000 | $0 | 1/16/2026 | View on chart |
| TARA | ▼ Sell | Open Market | 21,224 | $96K | 3/26/2025 | View on chart |
| TARA | ▲ Buy | Grant | 24,500 | $0 | 1/24/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 6,554 | $31K | 1/21/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 2,157 | $13K | 1/3/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 3,049 | $6K | 1/19/2024 | View on chart |
| TARA | ▲ Buy | Grant | 23,000 | $0 | 1/19/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 5,229 | $12K | 1/10/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 1,899 | $4K | 1/3/2024 | View on chart |
| TARA | ▲ Buy | Grant | 19,900 | $0 | 1/19/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 5,225 | $16K | 1/10/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 2,159 | $6K | 1/3/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 4,603 | $29K | 1/10/2022 | View on chart |
| TARA | ▲ Buy | Grant | 14,100 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment
Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.